JOIN OUR FREE WEBINAR
Beyond Hunger: How Oral GLP-1s Are Rewriting the Neuroscience of Craving
A physician-led clinical briefing on the next generation of metabolic medicine
Oral small-molecule GLP-1s, reward-circuit pharmacology, and the patent cliff approaching obesity care.
- May 27 | 6:30 PM CT
- ~45 minutes + Q&A
Your Host
Dr. Jay K Joshi
Medical Director, Prestige 2.0
Complete the form below to secure your spot today. Only a few spots left.
🔐 Your privacy is 100% protected.
Physician-led protocol. Eligibility determined during consultation.
Watch: Why GLP-1 Alone Isn’t Enough
The GLP-1+ Advantage: Precision-Matched To Your Body.
The Metabolism Track (GLP-1 & NAD+): Optimized for those focused on appetite control and cellular energy to stop the rebound effect.
The Composition Track (GLP-1 & Sermorelin): Targeted support for maintaining lean muscle so you lose fat, not strength.
Limited number of free spots available!
- Physician-guided care
- Multiple clinic locations
- Telemedicine consultations available
WHO THIS WEBINAR IS FOR
What You’ll Learn in This Free Webinar
- The reward-circuit story. Why GLP-1 is acting on the central amygdala and the mesolimbic dopamine pathway and why patients are noticing it in cravings, alcohol use, and compulsive behavior.
- The oral GLP-1 pivot. Bioavailability, dosing, and what is genuinely different about oral small-molecule agents like orforglipron versus injectable peptides.
- The addiction indication. What Phase 2 and Phase 3 trials are showing in alcohol use disorder and nicotine dependence and where the regulatory pathway is heading.
- The patent cliff. What generic semaglutide means for US pricing, insurance coverage, and the future of compounded GLP-1.
- Clinical decision-making. When oral makes sense, when injection still does, and what to ask your physician before switching.
Limited number of free spots available!
GLP-1 is becoming a reward-circuit drug.
GLP-1 receptors are densely expressed in the central amygdala and along the mesolimbic dopamine pathway — the circuitry responsible for reward-driven behavior, including overeating, alcohol use, nicotine dependence, and compulsive engagement with reward stimuli.
NIH-funded research and a growing number of Phase 2 and Phase 3 trials are showing that GLP-1 activation modulates reward signaling. Patient-reported effects; reduced cravings, diminished "food noise," lower interest in alcohol and nicotine are consistent with this mechanism.
This is not a fringe finding. It is the emerging center of gravity in the field.
The pharmacology of oral GLP-1 is genuinely different.
Injectable GLP-1s bypass the gastrointestinal tract entirely. Bioavailability is high and predictable.
Oral peptide GLP-1 (oral semaglutide) has to survive stomach acid, evade enzymatic degradation, and cross the gut wall. Bioavailability is approximately 1% of the oral dose, and absorption is sensitive to timing, food, and fluid volume.
Oral small-molecule GLP-1s — orforglipron is the lead candidate — are not peptides at all. They solve the absorption problem chemically, not pharmaceutically. The pharmacokinetics are meaningfully different.
The clinical implication: oral and injectable are not interchangeable on dose, and switching is not a one-to-one translation.
Limited number of free spots available!
About Prestige 2.0
Our approach is built around:
- Ongoing monitoring, coaching, and clinical support
- Fully individualized care plans
- Evidence-based treatment protocols
- Physician-led medical oversight
At Prestige 2.0, we don’t just prescribe medication — we teach the GLP-1+ system.
That means a structured approach to dosing strategy, clear nutrition guardrails, realistic exercise expectations, ongoing monitoring, and built-in accountability. Our model is physician-led, individualized, and designed to help patients move beyond short-term results toward sustainable, long-term change.
Limited number of free spots available!
Frequently Asked Questions (FAQ)
What You Should Know Before the Webinar
Is this a sales presentation?
No. It is a physician-led clinical briefing. There is no pitch, no product, and no upsell during the session.
Is there a replay?
Yes. Registered attendees receive the replay. Live Q&A is only available during the live session.
Who is this for?
Patients on GLP-1, patients considering GLP-1, healthcare-curious adults, employer benefit sponsors, and anyone tracking the direction of obesity medicine.
Is this CME-accredited?
This is a patient-facing educational briefing, not a CME activity.
How long is the briefing?
Approximately 60 minutes, including live Q&A.
Can I submit a question in advance?
Yes. Registered attendees can submit questions ahead of time through the registration confirmation email.
Limited number of free spots available!
Why We Are Trusted?
This briefing is grounded in published, peer-reviewed pharmacology and ongoing clinical trial data. Topics discussed include findings from NIH-funded reward-circuit research, late-stage trial readouts on oral small-molecule GLP-1 agents, and the published pharmacokinetic literature on oral peptide absorption. Dr. Joshi will distinguish clearly between established findings, emerging evidence, and speculative interpretation.
The next 24 months will reshape obesity care.
Patients who understand all three will make better clinical and financial decisions over the next two years. That is the purpose of this briefing.
- The migration of GLP-1 from injectable peptide to oral small-molecule chemistry.
- The expansion of GLP-1 indications into reward-circuit applications - alcohol use disorder, nicotine dependence, compulsive behavior.
- The approaching patent cliff on semaglutide, with generic competition first arriving in non-US markets.
Limited number of free spots available!
Over 2000+ patients have attended prior Prestige 2.0 clinical briefings.
Live Q&A happens once.
The replay is available to registered attendees, but the live Q&A — where Dr. Joshi answers specific patient questions in real time — only happens on May 27 at 6:30 PM CT.
If you have a question about your own care, the live session is where it gets addressed.
Limited number of free spots available!